Page results
-
This page is for cancer patients receiving immunotherapy treatment.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
Doctors at UCLH and University College London (UCL) have developed a digital decision-making aid, MENO.pause, to help clinicians manage menopause symptoms in the best way for individual patients’ health conditions.
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
This page tells you about the procedure known as a Bronchial Artery Embolisation (BAE).
-
This page explains how to print your information from the MyCare website and app.
-
A breathing aid that can help keep Covid-19 patients out of intensive care, adapted by mechanical engineers at UCL and clinicians at UCLH working with Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP), has been approved for use in the NHS.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
File results
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2019/16 Antenatal unit questionnaire
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI2017328 Use of variable rate intravenous insulin infusion